- Diabetes is an epidemic disease and is estimated to affect >300 million people worldwide in 2025 . Type 2 diabetes (T2D) management is a combination of diet, lifestyle modifications, and drug therapy. Recently, many studies have shown remission of T2D in obese population [2–6]. Buchwald et al.  in his systemic review and meta-analysis showed that diabetes remission rates were 99% (95% confidence interval, 97%–100%) after biliopancreatic diversion, 84% (95% confidence interval, 77%–90%) after Roux-en-Y gastric bypass (RYGB), and 48% (95% confidence interval, 29%–67%) after gastric banding.
- Randomized trials of bariatric surgery versus lifestyle treatment likely enroll highly motivated patients, which may limit the interpretation and generalizability of study findings. The objective of this study was to assess the feasibility of a population-based shared decision-making (SDM) approach to recruitment for a trial comparing laparoscopic Roux-en-Y gastric bypass surgery with intensive lifestyle intervention among adults with mild to moderate obesity and type 2 diabetes.
- We report the first human experience with an endoscopic duodenal-jejunal bypass sleeve (DJBS) in a community hospital.
- Laparoscopic adjustable gastric banding (LAGB) brings several unique aspects to bariatric surgery. It has provided a very safe, effective, reversible, and adjustable system that is widely applicable. The first human LAGB procedure, using the Lap-Band system (INAMED Health, Santa Barbara, CA), was performed on September 1, 1993 . Since then, more than 130,000 Lap-Band devices have been placed, and more than 100 peer-reviewed reports on its use have been published. The extent of the literature on the outcomes of LAGB surgery is comparable (and, in certain aspects, superior) to that on alternative bariatric surgery.